BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28643125)

  • 21. PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells.
    Chuang CY; Chang CP; Lee YJ; Lin WL; Chang WW; Wu JS; Cheng YW; Lee H; Li C
    Oncol Rep; 2017 Aug; 38(2):1115-1123. PubMed ID: 28656289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
    Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
    Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
    Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
    Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling.
    Yao B; Gui T; Zeng X; Deng Y; Wang Z; Wang Y; Yang D; Li Q; Xu P; Hu R; Li X; Chen B; Wang J; Zen K; Li H; Davis MJ; Herold MJ; Pan HF; Jiang ZW; Huang DCS; Liu M; Ju J; Zhao Q
    Genome Med; 2021 Apr; 13(1):58. PubMed ID: 33853662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer.
    Yamamoto T; Hayashida T; Masugi Y; Oshikawa K; Hayakawa N; Itoh M; Nishime C; Suzuki M; Nagayama A; Kawai Y; Hishiki T; Matsuura T; Naito Y; Kubo A; Yamamoto A; Yoshioka Y; Kurahori T; Nagasaka M; Takizawa M; Takano N; Kawakami K; Sakamoto M; Wakui M; Yamamoto T; Kitagawa Y; Kabe Y; Horisawa K; Suzuki A; Matsumoto M; Suematsu M
    Cancer Res; 2024 Apr; 84(7):1065-1083. PubMed ID: 38383964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
    Altan B; Yokobori T; Ide M; Mochiki E; Toyomasu Y; Kogure N; Kimura A; Hara K; Bai T; Bao P; Suzuki M; Ogata K; Asao T; Nishiyama M; Oyama T; Kuwano H
    Gastric Cancer; 2016 Jul; 19(3):789-97. PubMed ID: 26472729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
    Zhang Y; Bi J; Zhu H; Shi M; Zeng X
    Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
    Anborgh PH; Lee DJ; Stam PF; Tuck AB; Chambers AF
    Expert Opin Ther Targets; 2018 Aug; 22(8):727-734. PubMed ID: 30025479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.